The report reviews pipeline therapeutics for Graft Versus Host Disease
(GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
A review of the Graft Versus Host Disease
(GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Acute graft versus host disease
after liver transplantation: patterns of lymphocyte chimerism.
Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease
Graft versus Host Disease
(GvHD) is one of the potentially fatal complications of hematopoietic stem cell transplantation (HCT).
Read more inside Graft Versus Host Disease
The companies entered into the original license agreement in August 2003, granting JCR the right to commercialize a stem cell drug in Japan designed to treat the effects of Graft versus Host Disease
(GvHD) in patients undergoing bone marrow transplantation to treat leukemia.
Overly aggressive immune responses have become associated with many serious diseases such as arthritis, graft versus host disease
, inflammatory bowel disease, and other conditions.
Osiris recently became the first company to receive Fast Track designation from FDA for a similar stem cell product, Prochymal(TM), for the treatment of graft versus host disease
in cancer patients.
Completion of the pivotal phase III clinical trial for lead product orBec(R) (beclomethasone 17, 21-dipropionate) for the treatment of intestinal graft versus host disease
Moreover, clinicians have reported positive results using ATG-FRESENIUS S for conditioning regimens and prevention of graft versus host disease
in bone marrow transplantation.
His extensive licensing experience will be essential in building value in our biotherapeutic programs as we are eagerly awaiting the results of our pivotal Phase III clinical trial of orBec(R) in intestinal graft versus host disease